WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advi...(ot be able to do so on reasonable terms ...),Health

Date:5/18/2009

ot be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2008 and the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

    Contact:
    Vida Communication (Media)                     The Trout Group (Investors)
    On Behalf of WaferGen                          On Behalf of WaferGen
    Tim Brons                                      Peter Rahmer
    415-675-7400                                   646-378-2973
    tbrons@vidacommunication.com                   San Francisco, CA

                                                   or

                                                   Christine Yang
                                                   646-378-2929
                                                   New York, NY

'/>"/>

SOURCE WaferGen Biosystems, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. WaferGen and Leading Academic Medical Center Establish Genotyping Research Collaboration to Validate SNPs in Breast Cancer Using SmartChip(TM) Real-Time PCR System
2. WaferGens Chief Scientific Officer to Deliver Executive Talk at Malaysian Ministry of Science, Technology and Innovations PCR Conference
3. WaferGens SmartChip(TM) Real-Time PCR System to Begin Alpha Testing at University of Pittsburgh Medical School
4. WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications
5. Bausch & Lomb Appoints Global Vision Care and North American Vision Care Presidents
6. iMedica Appoints Dr. Ray Fabius, Global Physician Executive, to Board of Directors
7. The Candies Foundation Appoints Bristol Palin As Teen Ambassador
8. WuXi PharmaTech Appoints Hao Zhou as Vice President of Finance
9. Shamir Optical Industry Ltd. Appoints Amos Netzer as New Chief Executive Officer
10. Protein Sciences Corporation Appoints New Board of Directors
11. China Pharma Holdings, Inc. Appoints Chief Financial Officer and Board Member